

Human Herpes Virus-6 Meningoencephalitis in an Immunocompetent Peripartum Lady

Sonali Bhattu*, SH Talib**, Abdulla lbji***, Amjad Syed Ali****

Abstract

We describe a case of Human herpesvirus-6 (HHV-6) meningoencephalitis in an immunocompetent peripartum lady who presented to the emergency department with febrile illness, disorientation, myalgia and altered levels of consciousness. Encephalitis occurs in immunocompromised people and is the most feared complication of HHV-6 disease. Two strains of this virus are A and B. HHV-6B is the predominant strain. This virus is characterised by lifelong latency in peripheral blood mononuclear cells and brain tissues. Hence, latent infection/reactivation occurs in immunocompromised patients. The literature is scanty about CNS involvement in immunocompetent adult patients. Meningoencephalitis developing in an immunocompetent peripartum case is unreported in Asian literature. HHV-6 infection should be kept in mind in any immunocompetent patient with meningoencephalitis of uncertain aetiology.

Key words: HHV-6, meningoencephalitis, immunocompetent, peripartum, acyclovir.

Introduction

HHV-6 is the sixth herpes virus discovered infection in humans and is nearly ubiquitous in the first two years of life with sero-prevalence rate of 95% in most studies¹. The virus was isolated in 1986 among patients of lymphoproliferative diseases. Encephalitis occurs in immunocompromised patients and is the most feared complication of HHV-6 disease. Infection by this Beta – Herpes virus is characterised by two strains A and B. HHV-6B is the predominant strain of the virus. HHV-6A disease has been documented to cause illness in only immunosuppressed host². The clinical difference is not well documented, so for the purposes of management, they are treated the same. HHV-6 is also characterised by lifelong latency in peripheral blood mononuclear cells and brain tissues following primary infection³. The latent infection or reactivation often occurs in immunocompromised patients and may cause fever, pneumonia, rashes, hepatitis and meningoencephalitis. Literature is scanty for central nervous system involvement in adult immunocompetent patients suffering from meningoencephalitis, especially in the peripartum period.

Case report

We describe a case of HHV-6 meningoencephalitis in an immunocompetent 25-year-old lady, who had recently delivered a baby. She had a history of pregnancy induced hypertension and was on oral Nifedipine 10 mg every 12 hourly. The records indicated her pregnancy was otherwise

uneventful. She had a normal delivery of a female baby weighing 2,900 g. She was discharged the next day, in an apparently healthy condition with normal vitals.

Two days post-delivery she developed febrile illness and altered levels of consciousness. She also offered history of headache and myalgia. Physical examination revealed healthy episiotomy wound with normal gynaecological examination. Her Pulse was 120 beats per minute, regular with good volume, blood pressure 140/100 mmHg (on Nifedipine 10 mg BD). Her respiratory rate was 20 breaths per minute with a temperature of 101° F. Cyanosis was absent. She had neck stiffness, right lateral rectus palsy and normal pupils. Owing to thick throat secretions and respiratory discomfort she was intubated for 4 days. Deep tendon reflexes were brisk with bilateral extensor plantar response. Muscle strength and tone were however normal. Other systemic examination was unrevealing. As she was febrile and showed signs of meningism, a diagnosis of meningoencephalitis was clinically entertained. The details of investigations on haemogram, renal function tests, liver function tests, thyroid function tests, urine and cerebrospinal fluid (CSF) examination done are shown in Table I. The neurotropic virus panel in CSF done by real time PCR (RT-PCR) is shown in Table II.

She was started on empirical parenteral Ceftriaxone, Acyclovir and Dexamethasone. Cranial magnetic resonance imaging (MRI) with contrast was performed on the second day of present hospitalisation. Neurophysician opined

*Professor, **Emeritus Professor, ***Resident, ****Assistant Professor, Department of Medicine, MGM Medical College, Chhatrapati Sambhaji Nagar - 431 003, Maharashtra.

Corresponding Author: Dr SH Talib, Emeritus Professor, Department of Medicine, MGM Medical College, Chhatrapati Sambhaji Nagar - 431 003, Maharashtra. Tel: 7875127786, E-mail: sftalib@gmail.com

hyperintensity in left temporal lobe, rest features were normal. Antibiotics were discontinued on 4th day of hospitalisation and treatment with acyclovir and dexamethasone continued for next 7 days. Her lateral rectus palsy, fever and plantar response receded after 7 days of acyclovir and dexamethasone therapy. Patient's general condition improved with normal mental status. She recovered from the disease without any morbidity and was discharged in healthy condition on 10th day of hospitalisation.

Table I: Showing investigations done on the patient on admission and discharge.

| Investigations | On Admission (Day 1) | On Discharge (Day 10) | Reference Range |
|-----------------------------------|-------------------------|-------------------------|-----------------|
| Haemogram | | | |
| Haemoglobin (gm%) | 11.7 | 10.5 | 13 - 16.2 |
| Total Leucocyte Count (c/cmm) | 19,050 | 9,630 | 4,000 - 10,000 |
| Platelet Count (million/cmm) | 326 | 231 | 150 - 410 |
| Packed Cell Volume (%) | 36.1 | 32.9 | 40 - 50 |
| Blood Sugar Random (BSR) (mg%) | 111 | 83 | |
| Renal Function Tests | | | |
| Blood Urea (mg/dL) | 14 | 20 | 19 - 43 |
| Serum Creatinine (mg/dL) | 0.5 | 0.6 | 0.8 - 1.5 |
| Serum Sodium (mEq/L) | 141 | 137 | 135 - 148 |
| Serum Potassium (mEq/L) | 4.0 | 3.7 | 3.5 - 5.5 |
| Liver Function Tests (LFT) | | | |
| Total Bilirubin (mg/dL) | 0.6 | Not done | 0.2 - 1.3 |
| Direct Bilirubin (mg/dL) | 0.4 | | 0 - 0.4 |
| Indirect Bilirubin (mg/dL) | 0.2 | | 0 - 0.8 |
| SGOT (U/L) | 33 | | 17 - 59 |
| SGPT (U/L) | 22 | | 21 - 72 |
| Alkaline Phosphatase (U/L) | 156 | | 38 - 125 |
| Total Proteins | 6.5 | Not done | |
| Serum Albumin (g/dL) | 3.3 | Not done | |
| Prothrombin Time | 11.8 Seconds | Not done | |
| C Reactive Protein (mg/dL) | 0.8 | Not done | 0.3 - 1 |
| Widal Test | Negative | - | |
| Dengue Ns1 Antigen | Non Reactive | - | |
| HIV 1/ HIV2 | Non Reactive | - | |
| HBsAg | Non Reactive | - | |
| Hepatitis C Virus Antigen | Negative | - | |
| TSH/FT3/FT4 | 0.88/1.97/1.20 | - | |
| Peripheral Blood Smear | Normocytic | Normocytic | |
| | Normochromic | Normochromic | |
| | Polymorphs 86% | Polymorphs 72% | |
| | Lymphocytes 14% | Lymphocytes 28% | |
| | with Adequate Platelets | with Adequate Platelets | |

| | | | |
|----------------------------|--------------|----------------------|-----|
| Urine Albumin Dipstick | Trace | Nil | Nil |
| Sugar | Nil | Nil | Nil |
| PLUS Cells | 1-2/HPF | Nil | Nil |
| Cerebrospinal Fluid | | | |
| Volume Examined | 2 ML | Colourless and Clear | |
| Coagulum | Absent | | |
| Cobweb | Absent | | |
| Cells | 20 Cells/HPF | | |
| Polymorphs | 30% | | |
| Lymphocytes | 70% | | |
| RBCs | Nil | | |
| Proteins | 92 mg/dL | | |
| Sugar | 63 mg/dL | | |

Table II: Neurotropic virus panel on Cerebrospinal Fluid (CSF).

| Method – Real Time Polymerase Chain Reaction (RTPCR) | |
|---|--------------|
| Name of the Virus | Result |
| Human Herpes Virus 6 (HHV6) | Detected |
| Herpes Simplex Virus (HSV1) | Not Detected |
| Herpes Simplex Virus (HSV2) | Not Detected |
| Parvovirus B19 | Not Detected |
| Epstein Barr Virus (EBV) | Not Detected |
| Varicella Zoster Virus (VZV) | Not Detected |
| Adenovirus | Not Detected |
| Enterovirus | Not Detected |
| Parechovirus | Not Detected |
| Varicella Zoster Virus (VZV) | Not Detected |
| Cytomegalovirus (CMV) | Not Detected |
| Human Herpes Virus 7 (HHV7) | Not Detected |

Discussion

HHV-6 infection has been associated with complications of varying severity in haematopoietic stem cell transplant (HSCT) recipients and to a lesser degree among solid organ transplant recipients. Mayo clinic data reported an incidence of HHV-6 encephalitis in 1.7% (9/571). While incidence was low the mortality rate in these patients was 50% and those who survived had high rates of persistent neurologic disease deficits⁴. Management of such patients described is controversial and ill defined, although, the treatment in immunocompromised patients with HHV-6 encephalitis, treatment is more rewarding with Acyclovir, Ganciclovir or valganciclovir⁵⁻⁸. HHV-6 viral infection is able to persist in the latent form in central nervous system or sometimes in cervical canal which may reactivate with resultant neurological diseases⁹. Yilmaz *et al* described 17 cases of HHV-6 meningoencephalitis in immunocompetent adults,

including their own case. Exact figures on mortality were not shown as database literature was inconclusive and did not describe this information completely¹⁰.

HHV-6 infection in immunocompetent adult individuals may manifest as a mononucleosis – like illness presenting with fever, lymphadenopathy and hepatitis. HHV-6 also has the ability to be chromosomally integrated (CiHHV-6), occurring in <1% of total population who newly acquire the infection and pass on the disease via vertical transmission. Yao *et al*⁹ examined for evidence of HHV-6 infection in CSF of encephalitis patients using PCR and HHV-6 antibody reactivity. HHV-6 DNA was detected in 40% encephalitis patients while the controlled group remained negative. Integrated chromosomal DNA complicated the result as among 1 - 2% of the general population CiHHV-6 is inherited from their parents, as demonstrated by some authorities². In immunocompromised patients PCR of HHV-6 DNA is often used for work-up with cell free CSF sample. This is considered as PCR technique of choice for the purpose. We did not use cell free CSF for the test. However, HHV-6 DNA was strongly positive suggestive of HHV-6 related CNS disease.

HHV-6 infection of CNS is reported with variable degrees of involvement in the pons, cerebral cortex, thalamus and medullary cord. HHV-6 exclusively involves medial temporal lobes (hippocampus and amygdala). Frontal lobes and cerebral lobes can also be involved. The MRI may show high signal T2W with mild enhancement¹⁰. The changes resolve as the condition improves. In our case the changes were noted in temporal lobe showing hyperintensities in the left side of temporal lobe that resolved post-therapy.

Infectious Disease Society of America recommends foscarnet or ganciclovir as first-line therapy for HHV-6 encephalitis; however, acyclovir who used in other cases with good outcome¹¹. The present case received acyclovir therapy with steroids for 10 days. Patient was reviewed two weeks later with normal vitals and without neurological deficits.

Conclusion

HHV-6 is a well known infection commonly seen in

immunosuppressed patients. Central nervous system infection resulting from HHV-6 in an immunocompetent host in the peripartum period with meningoencephalitis is rare. Data on this immunocompetent peripartum patients is unreported in the literature though limited cases of encephalitis are described among pregnant women. HHV-6 should be kept in mind when patients present with meningoencephalitis even among apparently immunocompetent people.

References

1. Yamanishi K, Okuno T, Shiraki K *et al*. Identification of human herpesvirus-6 as a causal agent for exanthem subitum. *Lancet* 1988; 1: 1065-7.
2. Endo A, Watanabe K, Ohye T *et al*. Molecular and virological evidence of viral activation from chromosomally integrated human herpesvirus 6A in a patient with X-linked severe combined immunodeficiency. *Clin Infect Dis* 2014; 59: 545-8.
3. Campadelli-Fiume G, Mirandola P, Menotti L. Human herpesvirus 6: an emerging pathogen. *Emerg Infect Dis* 1999; 5: 353-66.
4. Fida M, Hamdi AM, Bryson A *et al*. Long-term Outcomes of Patients With Human Herpesvirus 6 Encephalitis. *Open Forum Infect Dis* 2019; 6: ofz269.
5. Fotheringham J, Akhyani N, Vortmeyer A *et al*. Detection of active human herpesvirus-6 infection in the brain: correlation with polymerase chain reaction detection in cerebrospinal fluid. *J Infect Dis* 2007; 195: 450-4.
6. Soldan SS, Berti R, Salem N *et al*. Association of human herpes virus 6 (HHV-6) with multiple sclerosis: increased IgM response to HHV-6 early antigen and detection of serum HHV-6 DNA. *Nat Med* 1997; 3: 1394-7.
7. Donati D, Akhyani N, Fogdell-Hahn A *et al*. Detection of human herpesvirus-6 in mesial temporal lobe epilepsy surgical brain resections. *Neurology* 2003; 61: 1405-11.
8. Birnbaum T, Padovan CS, Sporer B *et al*. Severe meningoencephalitis caused by human herpesvirus 6 type B in an immunocompetent woman treated with ganciclovir. *Clin Infect Dis* 2005; 40: 887-9.
9. Yao K, Honarmand S, Espinosa A *et al*. Detection of human herpesvirus-6 in cerebrospinal fluid of patients with encephalitis. *Ann Neurol* 2009; 65: 257-67.
10. Yilmaz M, Yasar C, Aydin S *et al*. Detection of human herpesvirus-6 in cerebrospinal fluid of patients with encephalitis. *Clin Neurol Neurosurg* 2018; 171: 106-8.
11. Tunkel AR, Glaser CA, Bloch KC *et al*. The management of encephalitis: clinical practice guidelines by the Infectious Diseases Society of America. *Clin Infect Dis* 2008; 1: 303-27.